Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement. Read More

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement

Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement